We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome

This study is currently recruiting participants.
Verified November 2017 by GlaxoSmithKline
Sponsor:
ClinicalTrials.gov Identifier:
NCT02631538
First Posted: December 16, 2015
Last Update Posted: November 20, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
GlaxoSmithKline
  Purpose

This study is a multi-national, multi-center, double-blind (sponsor open), randomized, placebo-controlled trial in subjects with active primary Sjögren's syndrome designed to understand the safety and tolerability profile of belimumab/ rituximab co-administration and of belimumab monotherapy; and to evaluate whether either co-administration therapy or belimumab monotherapy has a substantive effect on disease activity.

This study will consist screening period, double blind treatment period, a general follow-up period and individualized follow-up period. Approximately 70 subjects will be recruited into the study initially. At Day 0, subjects will be randomized 1:2:2:2 to one of the four treatment arms placebo arm, belimumab monotherapy arm, co-administration therapy arm and rituximab monotherapy arm. Once a sufficient number of subjects have completed the Week 24, interim analyses and sample size re-estimation will be conducted. The total number of subjects randomized may increase following sample size re-estimation up to a maximum of 120 recruited into the study.

Subjects in all arms will receive investigational product (IP) until Week 52 (completion of the treatment phase). All subjects will enter a 16-week general follow-up period after the Week 52 visit or after discontinuation if a subject discontinues IP and withdraws from the treatment phase visits prior to Week 52.

After completing the general follow-up period, subjects with cluster of differentiation (CD)19+ B-cell levels below the lower limit of normal (or less than 90 percent [%] of baseline, if baseline value was below lower limit of normal [LLN]) will enter an individualized safety follow-up phase and return to the clinic for visits every 12 weeks with monthly calls between visits to evaluate subjects for any serious adverse events (SAEs) related to IP or study participation, fatal SAEs, and designated adverse event of special interests (AESIs) (i.e., infections, malignancies, or depression, suicide/self-injury), and to check concomitant medications.

The total duration of participation of a subject in this study will be approximately up to a maximum of 2 years (i.e., up to Week 104).


Condition Intervention Phase
Sjogren's Syndrome Drug: Belimumab Drug: Rituximab Drug: Placebo belimumab Drug: Placebo rituximab Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double Blind (Sponsor Open), Comparative, Multicenter Study to Evaluate the Safety and Efficacy of Subcutaneous Belimumab (GSK1550188) and Intravenous Rituximab Co-administration in Subjects With Primary Sjögren's Syndrome

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Number of participants with SAEs [ Time Frame: 104 weeks ]
    An SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations based on medical or scientific judgment and is associated with liver injury and impaired liver function

  • Number of participants with AESIs [ Time Frame: 104 weeks ]
    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AESI are malignancies, post-injection systemic reactions, infections, depression/ suicidality/ self-injury, and deaths


Secondary Outcome Measures:
  • The European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) score over time [ Time Frame: Screening, Week 12, Week 24, Week 36, Week 52, Week 68 and final follow up (assessed up to Week 104) ]
    The ESSDAI is an assessment of disease activity across twelve different clinically relevant domains for subjects with Sjögren's syndrome. ESSDAI will be assessed by the treating physician (preferably the same physician at each visit).

  • Stimulated salivary flow over time [ Time Frame: Screening, Week 12, Week 24, Week 36, Week 52, Week 68 and final follow up (assessed up to Week 104) ]
    Stimulated salivary flow rate will be assessed as entry criteria to ensure that subjects entered into the study have residual glandular function. Subjects with 0.0 milliliter per min (mL/min) unstimulated salivary flow rate may qualify for the study on the basis of stimulated salivary flow greater than 0.05 mL/min.

  • Oral dryness numeric response scale over time [ Time Frame: Screening, Week 12, Week 24, Week 36, Week 52, Week 68 and final follow up (assessed up to Week 104) ]
    Subjects are required to have symptomatic oral dryness as assessed by a score of at least 5 points on the 10 point numerical response scale.

  • B cell quantification within salivary gland biopsy at Week 24 [ Time Frame: Week 24 ]
    The quantification of B cells, such as a change in B/T cell ratio is measured by immunohistochemistry (IHC) analysis of B and T cell numbers within lymphoid foci in the salivary gland


Estimated Enrollment: 70
Actual Study Start Date: February 17, 2016
Estimated Study Completion Date: January 28, 2020
Estimated Primary Completion Date: May 21, 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Subjects will receive belimumab placebo weekly subcutaneous injections to Week 52 and rituximab placebo infusions at Weeks 8 and 10.
Drug: Placebo belimumab
The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.
Drug: Placebo rituximab
Placebo rituximab will be provided as solution for infusion. It is a clear, colorless liquid.
Experimental: Belimumab monotherapy
Subjects will receive 200 mg weekly subcutaneous injections of belimumab to Week 52 and placebo rituximab infusions at Weeks 8 and 10.
Drug: Belimumab
Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.
Drug: Placebo rituximab
Placebo rituximab will be provided as solution for infusion. It is a clear, colorless liquid.
Experimental: Belimumab and Rituximab co-administration therapy
Subjects will receive belimumab 200 mg SC weekly for 24 weeks followed by weekly placebo belimumab injections to Week 52 with rituximab 1000 mg intravenously at Weeks 8 and 10.
Drug: Belimumab
Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.
Drug: Rituximab
Rituximab will be provided as a 100 mg concentrated solution for infusion. It is a clear, colorless liquid.
Drug: Placebo belimumab
The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.
Active Comparator: Rituximab monotherapy
Subjects will receive 1000 mg IV rituximab infusions at Weeks 8 and 10 and weekly subcutaneous injections of placebo belimumab to Week 52.
Drug: Rituximab
Rituximab will be provided as a 100 mg concentrated solution for infusion. It is a clear, colorless liquid.
Drug: Placebo belimumab
The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age >=18 years, at the time of signing the informed consent.
  • Documented Primary Sjögren's Syndrome by American European Consensus Group criteria including: either anti-Sjogren's-syndrome-related antigen A (SS-A) or anti-Sjogren's-syndrome-related antigen B (SS-B) positive.
  • Baseline unstimulated salivary flow >0.0 mL/min or evidence of glandular reserve function (stimulated baseline salivary flow >0.05 mL/min).
  • Symptomatic oral dryness (>=5/10 on subject completed numeric response scale).
  • Systemically active disease, ESSDAI >=5 points.
  • Male and female subjects; females of child bearing potential are eligible if using effective contraception: Female subject is eligible to participate if she is not pregnant (as confirmed by a negative urine human chorionic gonadotropin [hCG] test), not lactating, and at least one of the following conditions applies:

    1. Non-reproductive potential defined as: Pre-menopausal females with one of the following: Documented tubal ligation, Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion, Hysterectomy, Documented Bilateral Oophorectomy.

      Postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle stimulating hormone [FSH] and estradiol levels consistent with menopause). Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective contraception methods if they wish to continue their HRT during the study; otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment.

    2. Reproductive potential and agrees to follow one of the options in the GlaxoSmithKline (GSK) Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) requirements from 30 days prior to the first dose of study medication up to Week 68 after Day 0.
  • Ability to understand and comply with the protocol-required procedures and provision of informed consent.

Exclusion Criteria:

  • Diagnosis of secondary Sjögren's syndrome.
  • Active life-threatening or organ-threatening complications of Sjogren's-syndrome (SS) disease at the time of screening based on treating physician evaluation including but not restricted to (1) vasculitis with renal, digestive, cardiac, pulmonary or central nervous system (CNS) involvement characterized as severe, (2) active CNS or peripheral nervous system (PNS) involvement requiring high dose steroids, (3) severe renal involvement defined by objective measures, (4) lymphoma.
  • History of major organ transplant (including hematopoietic stem cell transplant).
  • History of malignancy within past 5 years (with the exception of adequately treated: [1] cervical carcinoma Stage 1B or less, [2] non-invasive basal cell and squamous cell skin carcinoma).
  • History of infection requiring long term systemic therapy including: (1) history of positive human immunodeficiency virus (HIV) serology, (2) positive serology for Hepatitis C virus (HCV), (3) positive serology for Hepatitis B (HB), defined as: HB surface antigen positive (HBsAg+) OR HB core antibody positive (HBcAb+).
  • Previous serious opportunistic or atypical infections or hospitalization for treatment of infection within 364 days of Day 0 or use of parenteral (intravenous [IV] or intramuscular [IM]) antibacterials, antivirals, anti-fungals, or anti-parasitic agents within 364 days of prior to Day 0.
  • Patients in a severely immunocompromised state.
  • History of an anaphylactic reaction to parenteral administration of contrast agents, human or murine proteins or monoclonal antibodies.
  • History of significant medical illness (or planned surgical procedure) which in the opinion of the investigator would interfere with the study procedures and / or assessments - including but not limited to immunoglobulin G4 (IgG4) disease or prior head or neck irradiation.
  • Severe heart failure (New York Heart Association, Class IV) or other severe, uncontrolled cardiac disease.
  • Tuberculosis (TB), defined as: prior history of TB infection; suspicion of TB infection or current TB infection
  • At risk of suicide, as indicated by a lifetime history of attempted suicide or significant suicidal ideation over the 6 months prior to the screening visit; or, if in the Investigator's judgment, the subject is at risk for a suicide attempt.
  • Neurological findings consistent with Progressive Multifocal Leukoencephalopathy (PML) - not otherwise explained - or confirmed PML.
  • Electrocardiogram (ECG) showing a clinically significant abnormality at Screening or showing an average corrected QT using Bazett's formula (QTcB) or corrected QT using Fridericia's formula (QTcF) interval >=450 milliseconds (msec) (>=480 msec for subjects with a Bundle Branch Block) over 3 consecutive ECGs.
  • Alanine aminotransferase (ALT) >2x upper limit of normal (ULN) and bilirubin >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
  • Use of systemic immunosuppressive or immunomodulatory agents including methotrexate, azathioprine, leflunomide, mycophenolate (including mycophenolate mofetil, mycophenolate mofetil hydrochloride, and mycophenolate sodium), mizoribine, calcineurin inhibitors [e.g., tacrolimus, cyclosporine], sirolimus, 6-mercaptopurine, or thalidomide within 60 days prior to Day 0.
  • Have received cyclophosphamide within 180 days prior to Day 0.
  • Have received anti- B lymphocyte stimulator (BLyS), anti-CD 20, anti-CD22 or anti-CD52 or any other B-cell depleting agent within 364 days prior to Day 0.
  • Have received abatacept or any biologic agent within 180 day prior to Day 0 (with exception of denosumab).
  • Have received intravenous immunoglobulin (IVIG) or plasmapheresis within 90 days prior to Day 0.
  • Have received oral steroid >10 milligram (mg) prednisone equivalent/day within 30 days prior to Day 0 or oral steroid >20 mg prednisone equivalent / day for a minimum of two consecutive weeks within 60 days prior to Day 0. Have received parenteral steroid within 60 days prior to Day 0.
  • Have received a live vaccine within 30 days of Day 0.
  • Current participation in any other interventional trial.
  • Planned blood donation during the treatment and follow up periods of the study.
  • Subjects who are unable or unwilling to administer, or to have a caregiver administer subcutaneous injections.
  • Drug or alcohol abuse or dependence.
  • History of hypersensitivity to belimumab and/or rituximab or known to have titers of human anti-mouse antibody or human anti-chimeric antibody or history of hypersensitivity reactions when treated with other diagnostic or therapeutic monoclonal antibodies.
  • Have an IgA deficiency (IgA level <10 milligram per deciliter [mg/dL]).
  • Any of the following screening laboratory values: White blood cells (WBC) <2 x 10^9/L; Neutrophils <1.5 x 10^9/Liter (L); Circulating IgG or IgM levels <lower limit of normal (according to central laboratory range); Aspartate aminotransferase (AST) >2.0 times the upper limit of normal; Alkaline phosphatase (ALP) >1.5 times the upper limit of normal; Bilirubin >1.5 times the upper limit of normal; CD4 count <400 cells per cubic millimetre (cells/mm^3); CD8 count <150 cells/mm^3; CD19+ B-lymphocyte counts <0.1 x 10^9/L.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02631538


Contacts
Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com

  Show 39 Study Locations
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT02631538     History of Changes
Other Study ID Numbers: 201842
First Submitted: December 14, 2015
First Posted: December 16, 2015
Last Update Posted: November 20, 2017
Last Verified: November 2017

Keywords provided by GlaxoSmithKline:
Subcutaneous
Rituximab
Intravenous
Safety
Efficacy
Sjogren's syndrome
Belimumab

Additional relevant MeSH terms:
Sjogren's Syndrome
Syndrome
Disease
Pathologic Processes
Arthritis, Rheumatoid
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Xerostomia
Salivary Gland Diseases
Mouth Diseases
Stomatognathic Diseases
Dry Eye Syndromes
Lacrimal Apparatus Diseases
Eye Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Rituximab
Belimumab
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Immunosuppressive Agents